MedPath

Lactobacillus Reuteri Strains for Gingivitis Reduction

Not Applicable
Completed
Conditions
Gingival Inflammation
Interventions
Dietary Supplement: L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets
Registration Number
NCT06234839
Lead Sponsor
Universidad Autonoma de San Luis Potosí
Brief Summary

The aim of the present study was to investigate the potential beneficial effects in volunteer young adults of orally administered L. reuteri (DSM 17938 and ATCC PTA 5289) on gingival inflammation. The null hypothesis was that no difference would be manifested by probiotic therapy regarding the conventional mechanical treatment (without probiotic administration).

Detailed Description

Aim. To investigate the potential beneficial effects in volunteer young adults of orally daily administered L. reuteri (DSM 17938 and ATCC PTA 5289) on gingival inflammation. The null hypothesis was that no difference would be manifested by probiotic therapy regarding the conventional mechanical treatment (without probiotic administration).

Methods. A randomized controlled parallel clinical trial was conducted in sixty young adults (18-35 yrs old) with chronic marginal gingivitis for one month. Initially, both study groups underwent conventional mechanical periodontal therapy/oral anti-plaque hygiene. However, the experimental group additionally received the administration of two daily tablets, containing both L. reuteri strains, for 30 days, while the control group did not. Different clinical outcome variables (plaque (PI) and gingival (GI) indices, bleeding on probing (BOP), and crevicular fluid volume (CFV)) were recorded and compared between the study groups, both at baseline and at the end of the interventions, 30 days later. Statistical descriptive and inferential tests were performed (data distribution normality, Student's t, and Wilcoxon-Mann-Whitney tests).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Non-smokers (at least for the last 6 months).
  • Initial mean gingival index (GI) between 1.5 - 2.
  • With a minimum of 20 teeth present in the oral cavity.
Exclusion Criteria
  • Periodontal pockets > 4 mm.
  • Recent intake of antibiotics or anti-inflammatory drugs and/or reception of dental prophylaxis.
  • Daily consumption of analgesics, probiotics, or oral antimicrobial rinses/gels.
  • Overweight (MCI >25).
  • Alcohol or recreative drug frequent consumers.
  • Pregnancy or breast-feeding.
  • Allergy or hypersensitivity to study products
  • Fixed orthodontic appliances.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Probiotic groupL. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tabletsThe experimental group received conventional mechanical periodontal therapy and oral anti-plaque hygiene training, plus the administration of two daily tablets, containing both L. reuteri strains, for 30 days.
Primary Outcome Measures
NameTimeMethod
Gingival index0, 7, 14, 21 and 30 days.

The Gingival Index (GI) scores each site on a 0 to 3 scale, with 0 being normal and 3, being severe inflammation characterized by edema, redness, swelling, and spontaneous bleeding.

Plaque index0, 7, 14, 21 and 30 days.

The plaque index assesses the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth, except the third molars. The bacterial plaque developer solution was used to define cumulative amounts of plaque with criteria from 0 to 5.

Bleeding on probing0, 7, 14, 21 and 30 days.

BOP describes bleeding induced by gentle manipulation of the tissue. The probing is typically completed to the depth of the gingival sulcus, or the area between the gingiva and the tooth.

Crevicular fluid volume0, 7, 14, 21 and 30 days.

Gingival crevicular fluid is an inflammatory exudate derived from the periodontal tissues. It is composed of serum and locally generated materials such as tissue breakdown products, inflammatory mediators, and antibodies directed against dental plaque bacteria.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculty of Dentistry, Universidad Autónoma de san Luis Potosi

🇲🇽

San Luis Potosi, Mexico

© Copyright 2025. All Rights Reserved by MedPath